ZNF114 Inhibitors
Chemical inhibitors of ZNF114 can interfere with various cellular processes to achieve functional inhibition of this protein. MLN4924, a NEDD8-activating enzyme inhibitor, disrupts the neddylation process, a post-translational modification that can be crucial for the proper functioning of ZNF114. By halting neddylation, MLN4924 prevents the conformational and functional maturation of ZNF114, leading to its inhibition. Similarly, Chloroquine, by raising the pH inside lysosomes, can obstruct the degradation pathway of cellular proteins, including ZNF114. This disruption can result in the accumulation of misfolded or aggregated forms of ZNF114, thereby hindering its activity. Proteasome inhibitors such as MG132, Lactacystin, Bortezomib, Epoxomicin, Carfilzomib, Oprozomib, Ixazomib, Velcade, Marizomib, and Delanzomib exert their inhibitory effects by preventing the degradation of ubiquitinated proteins. This blockage can lead to a build-up of proteins within the cell, which may include ZNF114. As a result, ZNF114 may become functionally inhibited due to the aggregation of misfolded proteins or its sequestration in a nonfunctional state.
The inhibition of the proteasome by these compounds can lead to an increase in the cellular levels of ZNF114, which, paradoxically, results in a decrease in its functional activity due to the disruption of normal protein turnover and processing. The accumulation of ubiquitinated proteins, including potentially misfolded or nonfunctional ZNF114, can create a burden on the cell's quality control systems, such as the unfolded protein response, further contributing to the inhibition of ZNF114's normal function. By blocking the degradation pathway of ZNF114, these inhibitors impede the regular renewal process that is essential for the maintenance of its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits NEDD8-activating enzyme (NAE), which is essential for the neddylation process that modifies proteins including ZNF114. Inhibition of neddylation can lead to the functional inhibition of ZNF114 by preventing its proper conformational and functional maturation. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is known to alkalinize lysosomes, which can disrupt the degradation pathways of many proteins. This can lead to the accumulation of misfolded or aggregated proteins, potentially including ZNF114, hence functionally inhibiting its normal activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, potentially leading to the functional inhibition of ZNF114 by causing an accumulation of misfolded or nonfunctional proteins that may include ZNF114. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, which can include ZNF114, thereby functionally inhibiting its activity by the same mechanism as MG132. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib selectively inhibits the 26S proteasome, which can lead to the functional inhibition of ZNF114 by preventing its degradation, potentially resulting in the accumulation of nonfunctional or misfolded ZNF114. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor, and by blocking the degradation pathway, it may lead to the functional inhibition of ZNF114 by the accumulation of proteins destined for degradation, which may interfere with ZNF114's activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a proteasome inhibitor that can functionally inhibit ZNF114 by preventing its degradation, leading to potential aggregation or misfolding of ZNF114, disrupting its normal function. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is another proteasome inhibitor that can cause the functional inhibition of ZNF114 by preventing the degradation of proteins, possibly leading to the accumulation of nonfunctional ZNF114. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib inhibits the proteasome, which can functionally inhibit ZNF114 by preventing its proper degradation and processing, potentially causing an accumulation of the protein in a nonfunctional state. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor potentially leading to the functional inhibition of ZNF114 by interrupting its degradation, which may cause an accumulation of misfolded or dysfunctional ZNF114 proteins. | ||||||